Related articles

• Multicenter Study

  Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

  Lancet Gastroenterol Hepatol. 2018 Jun 1; 3 (6): 404-412.

• Comparative Study

  Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.

  World J. Gastroenterol. 2018 Dec 14; 24 (46): 5288-5296.

• Article

  Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.

  Scand. J. Gastroenterol. 2018 Jun 1; 53 (6): 692-699.

Show more related articles...